Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo

Metastatic colorectal cancer (mCRC) is the second leading cause of cancer deaths in the United States. More than 50% of patients with mCRC harbor mutations of the oncogenic driver RAS (KRAS or NRAS). Because directly targeting most mutations of RAS is technically challenging, researchers have concen...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Fan Fan, Susmita Ghosh, Reid Powell, Jason Roszik, Yongsun Park, Mary Sobieski, Alexey Sorokin, Clifford Stephan, Scott Kopetz, Lee M. Ellis, Rajat Bhattacharya
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Public Library of Science (PLoS) 2023-01-01
coleção:	PLoS ONE
Acesso em linha:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035898/?tool=EBI
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!